Evidence map›Paper›PMID 23644663›Full record

ArticleOncogene2014

CD99 suppresses osteosarcoma cell migration through inhibition of ROCK2 activity.

C Zucchini, M C Manara, R S Pinca, P De Sanctis, C Guerzoni, M Sciandra, P-L Lollini, G Cenacchi, P Picci, L Valvassori and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Oncogene, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
2.0field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 47 citations in OpenAlex.

  1. Review
  2. Article
  3. The blood-brain barrier: structure, regulation, and drug delivery.Signal transduction and targeted therapy · 2023
    Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

C ZucchiniDepartment of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy.
M C Manara1] CRS Development of Biomolecular Therapies, Bologna, Italy [2] Experimental Oncology Laboratory, Istituto Ortopedico Rizzoli, Bologna, Italy.
R S Pinca1] CRS Development of Biomolecular Therapies, Bologna, Italy [2] Experimental Oncology Laboratory, Istituto Ortopedico Rizzoli, Bologna, Italy.
P De SanctisDepartment of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy.
C Guerzoni1] Experimental Oncology Laboratory, Istituto Ortopedico Rizzoli, Bologna, Italy [2] PROMETEO Laboratory, STB, RIT Department, Istituto Ortopedico Rizzoli, Bologna, Italy.
M SciandraCRS Development of Biomolecular Therapies, Bologna, Italy.
P-L LolliniDepartment of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy.
G CenacchiDepartment of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy.
P PicciExperimental Oncology Laboratory, Istituto Ortopedico Rizzoli, Bologna, Italy.
L ValvassoriDepartment of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy.
K Scotlandi1] CRS Development of Biomolecular Therapies, Bologna, Italy [2] Experimental Oncology Laboratory, Istituto Ortopedico Rizzoli, Bologna, Italy [3] PROMETEO Laboratory, STB, RIT Department, Istituto Ortopedico Rizzoli, Bologna, Italy.
University of Bologna · ITIstituto Ortopedico Rizzoli · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

CD99, a transmembrane protein encoded by MIC2 gene is involved in multiple cellular events including cell adhesion and migration, apoptosis, cell differentiation and regulation of protein trafficking either in physiological or pathological conditions. In osteosarcoma, CD99 is expressed at low levels and functions as a tumour suppressor. The full-length protein (CD99wt) and the short-form harbouring a deletion in the intracytoplasmic domain (CD99sh) have been associated with distinct functional outcomes with respect to tumour malignancy. In this study, we especially evaluated modulation of cell-cell contacts, reorganisation of the actin cytoskeleton and modulation of signalling pathways by comparing osteosarcoma cells characterised by different metastasis capabilities and CD99 expression, to identify molecular mechanisms responsible for metastasis. Our data indicate that forced expression of CD99wt induces recruitment of N-cadherin and β-catenin to adherens junctions. In addition, transfection of CD99wt inhibits the expression of several molecules crucial to the remodelling of the actin cytoskeleton, such as ACTR2, ARPC1A, Rho-associated, coiled-coil containing protein kinase 2 (ROCK2) as well as ezrin, an ezrin/radixin/moesin family member that has been clearly associated with tumour progression and metastatic spread in osteosarcoma. Functional studies point to ROCK2 as a crucial intracellular mediator regulating osteosarcoma migration. By maintaining c-Src in an inactive conformation, CD99wt inhibits ROCK2 signalling and this leads to ezrin decrease at cell membrane while N-cadherin and β-catenin translocate to the plasma membrane and function as main molecular bridges for actin cytoskeleton. Taken together, we propose that the re-expression of CD99wt, which is generally present in osteoblasts but lost in osteosarcoma, through inhibition of c-Src and ROCK2 activity, manages to increase contact strength and reactivate stop-migration signals that counteract the otherwise dominant promigratory action of ezrin in osteosarcoma cells.

Indexed as

Cell Movement12E7 AntigenActin CytoskeletonAntigens, CDBlotting, WesternCadherinsCell AdhesionCell Adhesion MoleculesCell Line, TumorCytoskeletal ProteinsEzrinFluorescent Antibody TechniqueGene Expression Regulation, NeoplasticHumansImmunohistochemistryImmunoprecipitation12E7 AntigenAntigens, CDCadherinsCD99 protein, humanCell Adhesion MoleculesCytoskeletal ProteinsEzrinrho-Associated KinasesRNA, Small InterferingROCK2 protein, human

Identifiers

PMID23644663
OpenAlexW2063656324

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.